09C.105 :    Lung & other Thoracic Malignancies

Purpose:  To compare OS in patients with advanced NSCLC of non- adenocarcinoma tumor histology receiving erlotinib alone or CP-751,871 plus erlotinib.

Title:  Randomized, Open-Label, Phase 3 Trial of Erlotinib Alone or In Combination with CP-751,871 in Patients with Advanced Non-Small Cell Lung Cancer of Non-Adenocarcinoma Histology

09C.225 :    Lung & other Thoracic Malignancies

Purpose:  The primary objective is to demonstrate non-inferiority of overall survival (OS) when comparing subjects on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL to subjects treated with placebo.

Title:  A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 μg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy

09G.104 :    Lung & other Thoracic Malignancies

Purpose:  Primary Objectives: To estimate progression-free survival following application of this treatment regimen. Secondary Objectives: • To estimate tumor response rates following application of this treatment regimen. • To estimate treatment-related esophageal, pulmonary, hematologic, and other toxicity of patients with NSCLC receiving Erlotinib with hypofractionated thoracic radiotherapy • To evaluate overall survival • To evaluate a relationship between response rates and EGFR receptor status

Title:  A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients with Advanced or Inoperable Non-Small-Cell Lung Cancer

3 records found.